Get the Stockscreener App
23.07
0.30%
-0.07
After Hours:
22.00
-1.07
-4.64%
Septerna Inc stock is traded at $23.07, with a volume of 534.84K.
It is down -0.30% in the last 24 hours and up +56.73% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$23.14
Open:
$21.93
24h Volume:
534.84K
Relative Volume:
2.04
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.56%
1M Performance:
+56.73%
6M Performance:
+347.09%
1Y Performance:
+0.00%
1-Day Range:
$20.72
$23.29
1-Week Range:
$20.18
$23.61
52-Week Range:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
23.07 | 1.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Momentum divergence signals in Septerna Inc. chartJuly 2025 Summary & Community Verified Swing Trade Signals - newser.com
Septerna (NASDAQ:SEPN) Shares Gap DownHere's Why - MarketBeat
Will Septerna’s (SEPN) Latest Board Appointment Strengthen Its R&D Edge or Reinforce the Status Quo? - simplywall.st
Using data tools to time your Septerna Inc. exitMarket Performance Report & Real-Time Buy Zone Alerts - newser.com
Septerna Inc Stock Analysis and ForecastEarnings Beat Highlights & Maximize Gains Professionally - earlytimes.in
What drives Septerna Inc stock priceTechnical Breakout Signals & Outperform With Our Smart Trading Calculator - earlytimes.in
Septerna (SEPN): Evaluating Valuation Following Dr. Keith Gottesdiener’s Board Appointment - Yahoo Finance
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance
Visual analytics tools that track Septerna Inc. performancePortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Septerna (NASDAQ:SEPN) - MarketBeat
Multi asset correlation models including Septerna Inc.Trade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
Price momentum metrics for Septerna Inc. explainedGold Moves & Short-Term Trading Alerts - newser.com
How Septerna Inc. stock performs in high volatility markets2025 Winners & Losers & Daily Profit Focused Screening - newser.com
Septerna (NASDAQ:SEPN) Shares Up 8.5%Should You Buy? - MarketBeat
Septerna plunges as safety concerns force an end to early-stage trial - MSN
How hedge fund analytics apply to Septerna Inc. stockJuly 2025 Review & Accurate Intraday Trade Tips - newser.com
Real time breakdown of Septerna Inc. stock performanceJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Is Septerna Inc. stock entering bullish territory2025 Winners & Losers & Long-Term Growth Plans - newser.com
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn - Sahm
Are Options Traders Betting on a Big Move in Septerna Stock? - Yahoo Finance
Can Septerna Inc. stock hit analyst price targetsJuly 2025 Highlights & Entry Point Confirmation Signals - newser.com
Using RSI to spot recovery in Septerna Inc.Quarterly Risk Review & Long-Term Capital Growth Strategies - newser.com
Septerna Up 12%, Insider Buyers Are Up 219% - Yahoo Finance
Septerna appoints Keith Gottesdiener to board of directors By Investing.com - Investing.com Nigeria
Septerna Begins Phase 1 Trial for SEP-631 - MSN
Septerna, Inc. Expands Board with New R&D Chair - TipRanks
Septerna appoints Keith Gottesdiener to board of directors - Investing.com
Former Prime Medicine CEO and 20+ Drug Approval Leader Keith Gottesdiener Joins Septerna's Board - Stock Titan
What analysts say about Septerna Inc stockContrarian Investment Ideas & Low Risk Investment Growth - Early Times
Septerna (NASDAQ:SEPN) Stock Price Up 9.2%Should You Buy? - MarketBeat
Technical signs of recovery in Septerna Inc.Trade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
Septerna Inc. stock daily chart insightsExit Point & AI Enhanced Trading Alerts - newser.com
Real time scanner hits for Septerna Inc. explainedPrice Action & Reliable Price Breakout Signals - newser.com
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Septerna Inc Stock (SEPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | CEO and President |
Apr 02 '25 |
Option Exercise |
2.76 |
50,000 |
138,000 |
821,907 |
| Finer Jeffrey | CEO and President |
Apr 03 '25 |
Option Exercise |
2.76 |
5,000 |
13,800 |
826,907 |
| Ezekowitz Alan | Director |
Mar 07 '25 |
Buy |
6.93 |
13,319 |
92,270 |
117,420 |
| Ezekowitz Alan | Director |
Mar 06 '25 |
Buy |
6.00 |
41,355 |
248,130 |
104,101 |
| Ezekowitz Alan | Director |
Mar 05 '25 |
Buy |
5.82 |
37,835 |
220,260 |
62,746 |
| Ezekowitz Alan | Director |
Mar 04 '25 |
Buy |
6.35 |
7,491 |
47,544 |
24,911 |
| Finer Jeffrey | CEO and President |
Feb 25 '25 |
Buy |
5.68 |
10,000 |
56,765 |
764,907 |
| Finer Jeffrey | CEO and President |
Feb 26 '25 |
Buy |
5.70 |
4,000 |
22,796 |
768,907 |
| Finer Jeffrey | CEO and President |
Feb 27 '25 |
Buy |
5.80 |
3,000 |
17,400 |
771,907 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 25 '25 |
Buy |
5.59 |
6,282 |
35,116 |
36,282 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):